<?xml version="1.0" encoding="UTF-8"?>
<mods xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.loc.gov/mods/v3" version="3.1" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
  <titleInfo>
    <title>Pathogenesis of Middle East respiratory syndrome coronavirus</title>
  </titleInfo>
  <name type="personal">
    <namePart>Brand, Judith MA van den</namePart>
  </name>
  <name type="personal">
    <namePart>Smits,  Saskia L</namePart>
  </name>
  <name type="personal">
    <namePart>Haagmans,  Bart L</namePart>
  </name>
  <typeOfResource>text</typeOfResource>
  <originInfo>
    <issuance>monographic</issuance>
  </originInfo>
  <language>
    <languageTerm authority="iso639-2b" type="code">eng</languageTerm>
  </language>
  <physicalDescription>
    <form authority="marcform">print</form>
  </physicalDescription>
  <abstract>Human coronaviruses (CoVs) mostly cause a common cold that is mild and self-limiting. Zoonotic transmission of CoVs such as the recently identified Middle East respiratory syndrome (MERS)-CoV and severe acute respiratory syndrome (SARS)-CoV, on the other hand, may be associated with severe lower respiratory tract infection. This article reviews the clinical and pathological data available on MERS and compares it to SARS. Most importantly, chest radiographs and imaging results of patients with MERS show features that resemble the findings of organizing pneumonia, different from the lesions in SARS patients, which show fibrocellular intra-alveolar organization with a bronchiolitis obliterans organizing pneumonia-like pattern. These findings are in line with differences in the induction of cytopathological changes, induction of host gene responses and sensitivity to the antiviral effect of interferons in vitro when comparing both MERS-CoV and SARS-CoV. The challenge will be to translate these findings into an integrated picture of MERS pathogenesis in humans and to develop intervention strategies that will eventually allow the effective control of this newly emerging infectious disease.</abstract>
  <note type="statement of responsibility">Judith MA van den Brand [and two others]</note>
  <note>In: J Pathol. 2015 Jan; 235 (2): 175–184.
Published online 2014 Dec 11. doi: 10.1002/path.4458</note>
  <subject authority="mesh">
    <topic> Coronavirus Infections</topic>
    <topic>drug therapy</topic>
  </subject>
  <subject authority="mesh">
    <topic>Coronavirus Infections</topic>
    <topic>virology*</topic>
  </subject>
  <subject authority="mesh">
    <topic> Coronavirus Infections</topic>
    <topic>transmission</topic>
  </subject>
  <subject authority="mesh">
    <topic> Middle East Respiratory Syndrome Coronavirus</topic>
    <topic>drug effects</topic>
  </subject>
  <subject authority="mesh">
    <topic>Middle East Respiratory Syndrome Coronavirus</topic>
    <topic>isolation and purification</topic>
  </subject>
  <subject authority="mesh">
    <topic>Middle East Respiratory Syndrome Coronavirus</topic>
    <topic>pathogenicity</topic>
  </subject>
  <identifier type="uri">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7167882/pdf/PATH-235-175.pdf</identifier>
  <location>
    <url>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7167882/pdf/PATH-235-175.pdf</url>
  </location>
  <recordInfo>
    <recordCreationDate encoding="marc">201121</recordCreationDate>
    <recordChangeDate encoding="iso8601">20201121152257.0</recordChangeDate>
    <recordIdentifier source="DOH">D0001C000058</recordIdentifier>
  </recordInfo>
</mods>
